# A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Source: https://onco.cc/trials/nct07183189/  
OnCo record `nct07183189` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of SHR-A2009, Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT07183189 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 576 participants planned, started 2025-10-30 and due to reach its primary completion in 2032-11. Interventions recorded: SHR-A2009 ; Aumolertinib, Aumolertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07183189
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 576

## Sources

- ClinicalTrials.gov NCT07183189: https://clinicaltrials.gov/study/NCT07183189

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Aumolertinib](https://onco.cc/drugs/aumolertinib/), [SHR-A2009](https://onco.cc/drugs/shr-a2009/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07183189.json